CLINICAL CASE OF TREATMENT OF HEPATIC HAEMANGIOMA BY PROPRANOLOL IN THE NEWBORN

Cover Page
  • Authors: Kucherov Y.I.1, Zhirkova Y.V.2, Getman A.N.3, Ivleva S.A.3, Rekhviashvili M.G.3
  • Affiliations:
    1. Scientific Centre of Children's Health, Moscow Pirogov Russian National Research Medical University, Moscow
    2. N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation
    3. Scientific Centre of Children's Health, Moscow, Russian Federation
  • Issue: Vol 69, No 5-6 (2014)
  • Pages: 81-85
  • Section: PEDIATRICS: CURRENT ISSUES
  • URL: https://vestnikramn.spr-journal.ru/jour/article/view/433
  • DOI: https://doi.org/10.15690/vramn.v69i5-6.1048

Abstract


Clinical observation of conservative treatment of the left hemi-liver haemangioma by propranolol in the full-term newborn with initial symptoms of cardiac failure is presented. Extensive hepatic haemangioma was diagnosed prenatally on the 23–24th week of a gestation. After the birth the clinical diagnosis was confirmed by means of ultrasound investigation (the size — 50×30 mm) and by the data of computer tomography. The starter dose of propranolol made 0.5 mg/kg per day with further increase to 1,5 mg/kg per day; the preparation was prescripted at the age of 2 days of life. Episodes of decrease in cardiac rate to 95 b/min are noted among side effects. The child was dismissed for out-patient observation at the age of 12 days of life in a stable state. The positive dynamics is registered during ultrasound investigation in 6 months after initiation of treatment: lesion was significantly decreased in the size, and there was a considerable decrease in a blood flow. Treatment by propranolol in a dose of 1,5 mg/kg per day was continued. Modern data on possible mechanisms of propranolol effect at haemangiomas in children, regimen, side effects and complications are provided in discussion. It is noted that this drug can be considered as the agent of choice in the treatment of infantile haemangiomas in children of difficult localization since the neonatality period.


Yu. I. Kucherov

Scientific Centre of Children's Health, Moscow
Pirogov Russian National Research Medical University, Moscow

Author for correspondence.
Email: ykucherov@mail.ru

Russian Federation PhD, professor, Head of the Department of Premature Surgery and Intensive Care of RI of Pediatric Surgery of SCCH, professor of the Department of Pediatric Surgery of N.I. Pirogov Russian National Research Medical University

Yu. V. Zhirkova

N.I. Pirogov Russian National Research Medical University, Moscow, Russian Federation

Email: zhirkova@mail.ru

Russian Federation PhD, chief research scientist of the Department of Premature Surgery and Intensive Care of RI of Pediatric Surgery of SCCH, professor of the Department of Pediatric Anaesthesiology and Intensive Care of Faculty of advanced medical studies of N.I. Pirogov Russian National Research Medical University. Address: build. 1, 2, Lomonosovskii Avenue, Moscow, RF, 119991; tel.: +7 (499) 134-09-08

A. N. Getman

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: getman@nczd.ru

Russian Federation MD, Head of the Department of Computer tomography of X-ray diagnostics of Consultation-diagnostic center of SCCH. Address: build. 1, 2, Lomonosovskii Avenue, Moscow, RF, 119991; tel.: +7 (499) 134-10-65

S. A. Ivleva

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: ivlevasu@gmail.com

Russian Federation junior research scientist of the Department of Suprasonic Diagnostics of RI of Pediatrics of SCCH. Address: build. 1, 2, Lomonosovskii Avenue, Moscow, RF, 119991; tel.: +7 (499) 162-26-01

M. G. Rekhviashvili

Scientific Centre of Children's Health, Moscow, Russian Federation

Email: m.rekhviashvili@bk.ru

Russian Federation

resident physician of SCCH. Address: build. 1, 2, Lomonosovskii Avenue, Moscow, RF, 119991; tel.: +7 (499) 134-09-08

  1. Nazir Z., Pervez S. Malignant vascular tumors of liver in neonates. J. Pediatr. Surg. 2006; 41 (1): 49–51.
  2. Makin E., Davenport M. Fetal and neonatal liver tumours. Early Hum. Dev. 2010; 86 (10): 637–642.
  3. Kuroda T., Kumagai M., Nosaka S., Nakazawa A., Takimoto T., Hoshino K. Critical infantile hepatic hemangioma: results of a nationwide survey by the Japanese Infantile Hepatic Hemangioma Study Group. J. Pediatr. Surg. 2011; 46 (12): 2239–2243.
  4. Yeh I., Bruckner A.L., Sanchez R., Jeng M.R., Newell B.D., Frieden I.J. Diffuse infantile hepatic hemangiomas: a report of four cases successfully managed with medical therapy. Pediatr. Dermatol. 2011; 28 (3): 267–275.
  5. Drolet B.A., Frommelt P.C., Chamlin S.L., Haggstrom A., Bauman N.M. et al. Initiation and use of propranolol for infantile hemangioma: Report of a consensus conference. Pediatrics. 2013; 131 (1): 128–140.
  6. Sans V., de la Roque E.D., Berge J., Grenier N., Boralevi F., Mazereeuw-Hautier J., Lipsker D., Dupuis E., Ezzedine K., Vergnes P., Taieb A., Leaute-Labreze C. Propranolol for severe infantile hemangiomas: Follow-up report. Pediatrics. 2009; 124 (3): 423–431.
  7. Tan S.T., Itinteang T., Leadbitter P. Low-dose propranolol for multiple hepatic and cutaneous hemangiomas with deranged liver function. Pediatrics. 2011; 127 (3): 772–776.
  8. Ranne R.D., Ashcraft K.W., Holder T.M., Sharp R.J., Murphy J.P. Hepatic hemangioma: Resection using hypothermic circulatory arrest in the newborn. J. Pediatr. Surg. 1988; 23 (10): 924–926.
  9. Qureshi S.A., Gregg J.E.M., Galloway R.W. Computed tomographicmappearances of massive neonatal hemangioma of the liver: A case report. J. Comp. Tomography. 1988; 12 (2): 135–137.
  10. Draper H., Diamond I.R., Temple M., John P., Ng V., Fecteau A. Multimodal management of endangering hepatic hemangioma: Impact on transplant avoidance: a descriptive case series. J. Pediatr. Surg. 2008; 43 (1): 120–126.
  11. Mattioli L., Lee K.R., Holder T.M. Hepatic artery ligation for cardiac failure due to hepatic hemangioma in the newborn. J. Pediatr. Surg. 1974; 9 (6): 859–862.
  12. Morris J., Abbott J., Burrows P., Levine D. Antenatal diagnosis of fetal hepatic hemangioma treated with maternal corticosteroids. Obstetr. & Gynecol. 1999; 94 (5): 813–815.
  13. Leaute-Labreze C., Dumas de la Roque E., Horalevi F. Propranolol for severe hemangiomas of infancy. New Engl. J. Med. 2008; 358 (24): 2649–2651.
  14. Denoyelle F., Leboulanger N., Enjolras O., Harris R., Roger G., Garabedian E.N. Role of propranolol in the therapeutic strategy of infantile laryngotrachealhemangioma. Int. J. Pediatr. Otorhinolaryngol. 2009; 73 (8): 1168–1172.
  15. Ma X., Zhao T., Xiao Y., Yu J., Chen H., Huang Y., Liu J., Lin J., Ouyang T. Preliminary experience on treatment of infantile hemangioma with lowdose propranolol in China. Eur. J. Pediatr. 2013; 172 (5): 653–659.
  16. Mazereeuw-Hautier J., Hoeger P.H., Benlahrech S., Ammour A., Broue P., Vial J. Efficacy of propranolol in hepatic infantile hemangiomas with diffuse neonatal hemangiomatosis. J. Pediatr. 2010; 157 (2): 340–342.
  17. Schiestl C., Neuhaus K., Zoller S., Subotic U., Forster-Kuebler I., Michels R., Balmer C., Weibel L. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas. Eur. J. Pediatr. 2011; 170 (4): 493–501.
  18. Tan S.T., Itinteang T., Leadbitter P. Low-dose propranolol for infantile haemangioma. J. Plastic, Reconstruct. & Aesthet. Surg. 2011; 64 (3): 292–299.
  19. Fette A. Propranolol in use for treatment of complex infant hemangiomas: Literature review regarding current guidelines for preassessment and standards of care before initiation of therapy. Sci. World J. 2013; Article ID 850193: 1–9.
  20. Polyaev Yu.A., Kotlukova N.P., Postnikov S.S., Myl'nikov A.A., Garbuzov R.V., Konstantinov K.V., Narbutov A.G., Polyaeva T.Yu. Propranol for treating infantile hemangiomas. Detskaya khirurgiya = Pediatric surgery. 2013; 6: 35–38.

Views

Abstract - 33

PDF (Russian) - 2

PDF (English) - 1

Cited-By


PlumX



Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.